Synergy Pharmaceuticals Inc. (SGYP) Soars 9.17% on January 25

Synergy Pharmaceuticals Inc. (SGYP) had a good day on the market for Friday January 25 as shares jumped 9.17% to close at $0.41. About 15.58 million shares traded hands on 25,644 trades for the day, compared with an average daily volume of n/a shares out of a total float of 248.04 million. After opening the trading day at $0.41, shares of Synergy Pharmaceuticals Inc. stayed within a range of $0.45 to $0.40.

With today’s gains, Synergy Pharmaceuticals Inc. now has a market cap of $102.79 million. Shares of Synergy Pharmaceuticals Inc. have been trading within a range of $2.80 and $0.07 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company’s basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals Inc. is based out of New York, NY and has some 313 employees. Its CEO is Troy Hamilton.